An HLA-A*11:01-Binding Neoantigen from Mutated NPM1 as Target for TCR Gene Therapy in AML

SIMPLE SUMMARY: Acute myeloid leukemia (AML) is an aggressive hematological malignancy with poor prognosis. For AML relapses after chemotherapy, new and effective therapies are needed. In 30–35% of AMLs, a frameshift mutation in the nucleophosmin 1 gene (dNPM1) creates potential neoantigens that are...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Lee, Dyantha I., Koutsoumpli, Georgia, Reijmers, Rogier M., Honders, M. Willy, de Jong, Rob C. M., Remst, Dennis F. G., Wachsmann, Tassilo L. A., Hagedoorn, Renate S., Franken, Kees L. M. C., Kester, Michel G. D., Harber, Karl J., Roelofsen, Lisanne M., Schouten, Annemiek M., Mulder, Arend, Drijfhout, Jan W., Veelken, Hendrik, van Veelen, Peter A., Heemskerk, Mirjam H. M., Falkenburg, J. H. Frederik, Griffioen, Marieke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582585/
https://www.ncbi.nlm.nih.gov/pubmed/34771556
http://dx.doi.org/10.3390/cancers13215390

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582585/
https://www.ncbi.nlm.nih.gov/pubmed/34771556
http://dx.doi.org/10.3390/cancers13215390

Ejemplares similares